9688 Stock Overview Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Zai Lab Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Zai Lab Historical stock prices Current Share Price US$20.60 52 Week High US$25.80 52 Week Low US$10.56 Beta 0.98 1 Month Change 4.25% 3 Month Change 23.65% 1 Year Change 4.04% 3 Year Change -59.61% 5 Year Change n/a Change since IPO -66.23%
Recent News & Updates
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Zai Lab Limited Announces the Inclusion of Augtyro (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’S National Reimbursement Drug List Nov 28 Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million. Nov 16
Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million. Nov 15
Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China Nov 12
Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China Oct 29 See more updates
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Zai Lab Limited Announces the Inclusion of Augtyro (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’S National Reimbursement Drug List Nov 28 Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million. Nov 16
Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million. Nov 15
Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China Nov 12
Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China Oct 29
Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310 Oct 26
Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024 Oct 16
Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 Oct 09
Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 Sep 18 Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China Jul 16
Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024 Jul 11
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024 Jun 13 Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China May 15
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA May 14
Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024 Apr 16
Zai Lab Limited, Annual General Meeting, Jun 18, 2024 Mar 29
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer Mar 27
Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 19
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors Mar 15
Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024 Jan 26
Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC Jan 11
Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List Dec 13
Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023 Oct 19
Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China Aug 31
Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023 Jul 23 Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Jul 17
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis Jul 12
Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023 Jul 07 Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Jun 07
Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting Jun 02
Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib May 19
Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023 Feb 10
Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration Jan 31 Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors Jan 10
Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint Jan 06
Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development Jan 04
Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary Dec 16
Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer Nov 09
Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022 Oct 19
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting Sep 21
Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer Aug 04
Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022 Jul 20
China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited Jul 14
Zai Lab Limited Announces Breakthrough Therapy Designations Granted for Repotrectinib in China Jun 11
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Jun 04
Zai Lab Limited, Annual General Meeting, Jun 22, 2022 May 03
Zai Lab Limited to Report Q1, 2022 Results on May 10, 2022 Apr 21
Zai Lab Limited Announces Resignation of Tao Fu, Chief Strategy Officer Apr 03
Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 02, 2022 Feb 18
Zai Lab Limited to Report Fiscal Year 2021 Results on Mar 01, 2022 Feb 16
Zai Lab Limited Announces Treatment of First Patient in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer Jan 13
Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA Jan 07 Zai Lab Limited Announces China NMPA's Approval for NUZYRA® as A Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Zai Lab Announces Inclusion of Zejula® (Niraparib) in China's National Reimbursement Drug List for First-Line Ovarian Cancer Dec 05
Zai Lab Limited Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) Dec 01
Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib May 29
Zai Lab Announces First Patient Treated in Greater China in Metis Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer May 25
Zai Lab Limited Announces Recent Product Highlights and Anticipated Milestones May 11
Zai Lab Limited Appoints Ann Beasley as Chief Compliance Officer Mar 04
Zai Lab Expects to Receive Approval for and Launch QINLOCK and NUZYRA in China Mar 03
Zai Lab Limited to Report Fiscal Year 2020 Results on Mar 01, 2021 Feb 17
Turning Point and Zai Lab Broaden Announces Collaboration Jan 12 Zai Lab Limited Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
Zai Lab Limited Appoints Alan Sandler as President, Head of Global Development, Oncology Dec 02
Zai Lab Limited Announces Dosing of First Patient in China in the Global Pod1um-101 Study Evaluating Retifanlimab in Patients with Previously Treated, Microsatellite Instability-High Endometrial Cancer Oct 30
Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC Oct 06
Zai Lab Limited has completed a Follow-on Equity Offering in the amount of HKD 5.936996 billion. Oct 05 Shareholder Returns 9688 HK Biotechs HK Market 7D 0.2% -3.9% -0.5% 1Y 4.0% -5.7% 19.9%
See full shareholder returns
Return vs Market: 9688 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility Is 9688's price volatile compared to industry and market? 9688 volatility 9688 Average Weekly Movement 9.2% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 9688 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9688's weekly volatility (9%) has been stable over the past year.
About the Company Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Show more Zai Lab Limited Fundamentals Summary How do Zai Lab's earnings and revenue compare to its market cap? 9688 fundamental statistics Market cap HK$22.47b Earnings (TTM ) -HK$2.11b Revenue (TTM ) HK$2.77b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 9688 income statement (TTM ) Revenue US$355.75m Cost of Revenue US$395.21m Gross Profit -US$39.46m Other Expenses US$231.39m Earnings -US$270.85m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.50 Gross Margin -11.09% Net Profit Margin -76.13% Debt/Equity Ratio 16.9%
How did 9688 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 07:31 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Zai Lab Limited is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Meng BOCI Research Ltd. Linda Lu BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd.
Show 25 more analysts 
